pharma news

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

Bayer beats expectations with tougher times looming

Bayer's third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead.

News

AI features in UK plan to reduce animal testing

The UK government has set out an ambitious plan to phase out animal testing in scientific studies within five years.

News

NHS braces for thousands of redundancies

UK Health Secretary Wes Streeting has given the green light to a series of NHS reforms that will see around 18,000 administrative roles abolished.

News

FDA appoints veteran Pazdur to replace Tidmarsh

The FDA has steadied the ship at CDER by naming veteran regulator Richard Pazdur as director, although he was reportedly reluctant to take the job.

News

enGene's president and chief executive, Ron Cooper

Trial sets up filing for enGene bladder cancer gene therapy

enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.

Alkermes breaks new ground in narcolepsy with orexin drug

Bayer beats expectations with tougher times looming

AI features in UK plan to reduce animal testing

NHS braces for thousands of redundancies

FDA appoints veteran Pazdur to replace Tidmarsh

Trial sets up filing for enGene bladder cancer gene therapy

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks